Back to Search
Start Over
CMV-related anterior and intermediate uveitis in a kidney transplant recipient treated with belatacept.
- Source :
-
European journal of ophthalmology [Eur J Ophthalmol] 2023 Sep; Vol. 33 (5), pp. NP47-NP50. Date of Electronic Publication: 2022 Sep 13. - Publication Year :
- 2023
-
Abstract
- Introduction: Belatacept is associated with a higher incidence of cytomegalovirus (CMV) disease and atypical presentations. Ocular manifestations are rare, representing up to 5% of disease manifestations and previous cases consisted in isolated retinitis.<br />Case Description: Herein, we report the case of an 81-year-old kidney transplant recipient who developed an anterior and intermediate uveitis under belatacept therapy. The diagnosis was established using quantitative CMV polymerase chain reaction assays in the aqueous humor. Belatacept was interrupted and oral and topical valganciclovir treatments were instituted. Lesions however extended, leading to intensify the treatment by intra-venous and intra-vitreal ganciclovir injections. Visual acuity stabilized and ocular inflammation was finally controlled after 3 months.<br />Conclusion: Clinicians should be aware of CMV infection as a cause of anterior uveitis under belatacept-based regimen, even in the absence of symptoms suggestive of systemic CMV replication.
- Subjects :
- Humans
Aged, 80 and over
Antiviral Agents therapeutic use
Abatacept therapeutic use
Ganciclovir therapeutic use
Kidney Transplantation adverse effects
Cytomegalovirus Infections diagnosis
Cytomegalovirus Infections drug therapy
Uveitis, Anterior diagnosis
Uveitis, Anterior drug therapy
Uveitis, Intermediate drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1724-6016
- Volume :
- 33
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- European journal of ophthalmology
- Publication Type :
- Academic Journal
- Accession number :
- 36112857
- Full Text :
- https://doi.org/10.1177/11206721221126308